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ABSTRACT
Introduction: The efﬁcacy and safety of the
once-daily topical ophthalmic solutions,
alcaftadine 0.25% and olopatadine 0.2%, in
preventing ocular itching associated with
allergic conjunctivitis were evaluated.
Methods: Pooled analysis was conducted of two
double-masked, multicenter, active- and
placebo-controlled studies using the
conjunctival allergen challenge (CAC) model
of allergic conjunctivitis. Subjects were
randomized 1:1:1 to receive alcaftadine 0.25%,
olopatadine 0.2%, or placebo. The primary
efﬁcacy measure was subject-evaluated mean
ocular itching at 3 min post-CAC and 16 h after
treatment instillation. Secondary measures
included ocular itching at 5 and 7 min post-
CAC. Ocular itch was determined over all time
points measured (3, 5, and 7 min) post-CAC and
the proportion of subjects with minimal itch
(itch score\1) and zero itch (itch score = 0) was
also assessed.
Results: A total of 284 subjects were enrolled in
the two studies. At 3 min post-CAC and 16 h
after treatment instillation, alcaftadine 0.25%
achieved a signiﬁcantly lower mean itch score
compared with olopatadine 0.2% (0.50 vs. 0.87,
respectively; P = 0.0006). Alcaftadine
demonstrated a signiﬁcantly lower mean itch
score over all time points compared with
olopatadine (0.68 vs. 0.92, respectively;
P = 0.0390); both alcaftadine- and
olopatadine-treated subjects achieved
signiﬁcantly lower overall mean ocular itching
scores compared with placebo (2.10; P\0.0001
for both actives). Minimal itch over all time
Trial registration: ClinicalTrials.gov #NCT01470118 and
#NCT01732757.
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DOI 10.1007/s12325-014-0155-3points was reported by 76.1% of alcaftadine-
treated subjects compared with 58.1% of
olopatadine-treated subjects (P = 0.0121).
Treatment with alcaftadine 0.25% and
olopatadine 0.2% was safe and well tolerated;
no serious adverse events were reported.
Conclusion: Once-daily alcaftadine 0.25%
ophthalmic solution demonstrated greater
efﬁcacy in prevention of ocular itching
compared with olopatadine 0.2% at 3 min
post-CAC (primary endpoint), and over all
time points, 16 h post-treatment instillation.
Alcaftadine and olopatadine both provided
effective relief compared with placebo and
were generally well tolerated.
Keywords: Alcaftadine; Allergic conjunctivitis;
Antiallergic; Conjunctival allergen challenge
model; Ocular itch; Olopatadine;
Ophthalmology
INTRODUCTION
Allergic conjunctivitis is one of the most
common conditions requiring treatment by
ophthalmologists, optometrists, and allergists
[1]. While prevalence studies of conjunctivitis
alone are limited, epidemiologic data have been
derived from studies of the commonly
coexisting nasal symptoms or
rhinoconjunctivitis and are wide ranging with
large global variations [2, 3]. In the United
States, the Allergies in America survey
conducted in 2006 estimated that 14.2% of
the adult population had been affected by
allergic rhinoconjunctivitis, while a more
recent analysis based on National Health and
Nutrition Examination Survey III data in a
sample size of 20,010 adults found that 40% of
participants were affected by allergic
rhinoconjunctivitis in a 12-month period [2,
4, 5]. The International Study of Asthma and
Allergy in Childhood spanning 52 countries
reported that allergic conjunctivitis affects
1.4–39.7% of children and adolescents [6].
Ocular itching, the hallmark symptom of
allergic conjunctivitis, is often accompanied by
tearing, conjunctival redness, eyelid swelling,
and chemosis [7]. Allergic conjunctivitis is
mediated by immunoglobulin E-activated
degranulation of mast cells and the release of
a cascade of inﬂammatory mediators, including
histamine, in response to allergens [8, 9].
Histamine release and activation of histamine
H1 receptors in the conjunctiva leads to ocular
itching, while stimulation of H2 receptors on
the ocular surface results in vasodilation and is
associated with ocular redness, eyelid swelling,
and chemosis [10, 11]. Recent evidence suggests
that histamine binding to and activation of H4
receptors also play a role in allergic
conjunctivitis [12, 13]. Topical ophthalmic
antihistamines are the primary treatment
options for allergic conjunctivitis. Currently,
alcaftadine 0.25% and olopatadine 0.2% are the
only approved once-daily ophthalmic solutions
for allergic conjunctivitis in the United States
[14–19]. Both olopatadine and alcaftadine are
classiﬁed as dual-action antiallergic agents,
directly inhibiting histamine receptor
activation and indirectly reducing allergic
responses by stabilizing mast cells [20].
Clinical studies evaluating alcaftadine and
olopatadine as treatment options for allergic
conjunctivitis have used the conjunctival
allergen challenge (CAC) model to assess
clinical efﬁcacy [21, 22]. The CAC model was
designed to mimic the signs and symptoms of an
ocular allergic response in a controlled setting,
providing an alternative to environmental
allergy trials that are subject to variable allergen
exposures.Themodelhasbeenestablishedasthe
standardfordemonstratingefﬁcacyandsafetyof
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approval from the United States Food and Drug
Administration [21]. CAC testing consists of
instillation of the study drug or
comparator(s) into the eye followed by an
allergen challenge at a predetermined time
post-instillation. The effect is then graded using
a standardized severity scale, allowing
assessment of both the onset of action and
duration of effect [15, 17, 22–26].
Two recently completed similarly designed
studies are the ﬁrst to have compared the
efﬁcacy and duration of action of once-daily
alcaftadine 0.25% and olopatadine 0.2% and
placebo using the CAC model. The ﬁrst study
demonstratedthatalcaftadine0.25%wassafeand
effective in preventing signs and symptoms of
allergic conjunctivitis at both 16 and 24 h after
treatment instillation [26]. Differences in
treatment effect between alcaftadine 0.25% and
olopatadine 0.2% were most pronounced at the
earliest time point post-CAC, when alcaftadine
0.25% ophthalmic solution was statistically
superior to olopatadine 0.2% ophthalmic
solution. The second study further assessed
treatment outcome and conﬁrmed statistical
superiority of treatment with alcaftadine 0.25%
relative to olopatadine 0.2% in mean itch
reduction at the same time point post-CAC, at
16 haftertreatmentinstillation[27,28].Apooled
analysisofthedatacollectedfromthetwostudies
was completed to further characterize treatment
differences between alcaftadine 0.25% and
olopatadine 0.2% ophthalmic solutions.
METHODS
Study Design
Two multicenter, double-masked, randomized
active- and placebo-controlled trials
(ClinicalTrials.gov #NCT01470118 and
#NCT01732757) were conducted between
October 2011 and December 2012. Protocols
and informed consent forms were approved by
an independent review board (Alpha IRB, San
Clemente, CA, USA). Studies were conducted in
accordance with the Helsinki Declaration of
1975, as revised in 2000 and 2008, and
International Conference of Harmonisation
guidelines for Good Clinical Practice. Subjects
provided written informed consent (or assent
with a consent form signed by the subject’s
legally authorized representative) and signed
authorization for the Health Insurance
Portability and Accountability Act before any
study-related procedures or changes in
treatment.
Study Eligibility Criteria
Subject eligibility was identical for both studies.
Key inclusion criteria included subjects with a
history of ocular allergies and at least one
positive skin test within 24 months of the trial
start date to one of the following: cat dander,
grasses, ragweed, dog dander, cockroach, dust
mites, and trees; a best-corrected visual acuity
C0.6 on the logMAR scale (using the Early
Treatment Diabetic Retinopathy Study chart).
Subjects must have had a positive bilateral CAC
reaction (deﬁned as C2 itching and C2 redness
in the conjunctival vessel bed) within 10 min of
instillation of the last titration of allergen at
visit 1 and in at least two of three time points at
visit 2. All subjects agreed to avoid disallowed
medications and to discontinue contact lens
wear for the designated period.
Key exclusion criteria included subjects with
any baseline itching or a redness score[1 in any
vessel bed at each visit; any known allergy,
contraindications, or sensitivity to the study
medications; systemic or ocular condition in
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safety or trial parameters; ocular surgery within
3 months or refractive surgery within 6 months;
signs of active allergic conjunctivitis at the start
of any visit; presence of an active ocular
infection (bacterial, viral, or fungal); or history
of herpetic ocular disease. Owing to the
potential for randomization into a treatment
arm with a pregnancy category C therapeutic
[19], women who were pregnant or planning a
pregnancy, lactating, or of child-bearing age
and not using a medically acceptable form of
birth control for the entire period of the trials
were excluded. Subjects planning surgical
procedures during the trial period or those
with a history of retinal detachment, diabetic
retinopathy, or progressive retinal disease also
were ineligible.
Treatment and Assessments
Assessments from the three identical subject
visits of both studies were included in the
pooled analysis. At the ﬁrst study visit (day
-21 ± 3) or titration visit, allergens were
instilled in each eye followed by the subject
rating ocular itching severity at 10 min. Allergen
concentrations were increased serially until the
scores for both itching and conjunctival redness
reached C2.0. The maximal allergen
concentration used during this titration visit
was utilized for all subsequent visits. Itching
severity was graded using a ﬁve-point scale
(0–4), which allowed for half measures [15, 17,
21, 23–26]. Conjunctival redness was scored by
the investigator using a ﬁve-point ocular redness
scale (0–4) [15, 17, 21, 23–26].
At the second study visit (day -14 ± 3) or
conﬁrmation visit, allergen challenge using the
ﬁnal concentration from the ﬁrst visit was
performed to provide baseline data for those
subjects who continued to satisfy eligibility
criteria. Subjects rated ocular itching at 3, 5,
and 7 min after allergen instillation. Subjects
who met the qualifying criteria of post-
challenge bilateral itching C2 and who also
had bilateral conjunctival redness C2 at two of
the three time points (7, 15, and 20 min)
continued to visit 3A approximately 2 weeks
after visit 2.
At visit 3A (day 0), subjects were randomized
in a 1:1:1 ratio to receive one drop of masked
ophthalmic solution in both eyes: alcaftadine
0.25% ophthalmic solution (Lastacaft
,
Allergan, Inc., Irvine, CA, USA), olopatadine
0.2% ophthalmic solution (Pataday
, Alcon
Laboratories, Inc., Fort Worth, TX, USA), and
placebo: 0.3% hydroxypropyl methylcellulose
(Tears Naturale
 II, Alcon Laboratories, Inc.,
Fort Worth, TX, USA). Subjects returned
approximately 15.5 h after treatment
instillation (visit 3B) and were challenged
16 ? 1 h after study drug instillation in both
eyes using the same allergen and dose that had
elicited a positive reaction at visits 1 and 2. The
ﬁrst study also had a fourth visit that was used
to assess duration of action at 24 h post-
treatment instillation.
Efﬁcacy and Safety Parameters
The primary efﬁcacy endpoint was ocular
itching quantiﬁed by the subject at 3 min
post-CAC. Secondary efﬁcacy endpoints
included ocular itching evaluated by the
subject at 5 and 7 min post-CAC. Safety was
assessed by monitoring adverse events (elicited
and observed) throughout the studies, which
were then coded to system organ class and
preferred terms using the Medical Dictionary for
Regulatory Activities (MedDRA) version 13.1
[29].
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Both eyes of each subject were used for
statistical summaries and analyses. Categorical
variables were summarized using frequencies
and percentages, and continuous variables were
summarized using descriptive statistics,
including the number of observations, mean,
standard deviation, median, minimum, and
maximum values. Hypothesis testing, unless
otherwise indicated, was performed at the 5%
signiﬁcance level of type I error for two-sided
tests. The last observation carried forward
method was used to handle missing and
incomplete efﬁcacy data for the primary
measure. All secondary efﬁcacy measures were
analyzed using observed data only.
The intent-to-treat population, comprised of
all subjects who were randomized, was used for
the efﬁcacy analyses. A subset of the intent-to-
treat population, consisting of subjects who
completed the study with no protocol
violations, formed the per-protocol
population. This population was analyzed as
treated using observed data only and was used
for conﬁrmatory analyses. The safety
population included all randomized subjects
who received at least one dose of the study
treatment.
The primary efﬁcacy measure was
summarized by visit, time point, and
treatment group using descriptive statistics.
The differences in the means between
treatment groups were calculated, and mean
ocular itching scores for each of the treatments
were compared using two-sample t tests. In
addition, the nonparametric Wilcoxon rank-
sum test at each time point and repeated
measures analysis of covariance model
accounting for treatment and repeated time
measurements within each visit were
performed. Predeﬁned analyses on the primary
efﬁcacy data, ocular itch, both at each time
point and over all time points, included
comparisons of the number of subjects in each
group with minimal itch (deﬁned as itch score
\1), and the number of subjects with zero itch
(deﬁned as itch score = 0). Fisher’s exact test
was conducted for comparisons at each time
point and over all time points for each pair of
treatments (alcaftadine versus placebo,
olopatadine versus placebo, and alcaftadine
versus olopatadine). Secondary ocular itch
efﬁcacy measures were summarized using
descriptive statistics by visit, time point, and
treatment group, and statistically analyzed
in the same way as the primary measure.
Statistical analyses were performed using SAS

software, version 9.2 (SAS Institute Inc., Cary,
NC, USA).
RESULTS
Subject Demographics and Characteristics
A total of 284 subjects were enrolled in the two
clinical studies following screening visits 1 and
2; 96 subjects were randomized to receive
alcaftadine 0.25% ophthalmic solution, 95
received olopatadine 0.2% ophthalmic
solution, and 93 received placebo. Thirteen of
the 284 randomized subjects (alcaftadine
0.25%, n = 6; olopatadine 0.2%, n = 5;
placebo, n = 2) did not complete the studies.
The most common reasons for treatment
discontinuation across treatment arms were
loss to follow-up and adverse events (Fig. 1).
Subject demographics were well balanced
among the three treatment groups with no
signiﬁcant differences with regard to age,
gender, or race, while iris color differed
signiﬁcantly among groups (Table 1).
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For the primary efﬁcacy endpoint, ocular
itching at 3 min post-CAC and 16 h after
treatment instillation, alcaftadine 0.25%
achieved a statistically signiﬁcant lower mean
itch score compared with olopatadine 0.2%
(0.50 vs. 0.87, respectively; P = 0.0006; Fig. 2).
Analysis over all the time points measured (3, 5,
and 7 min) also demonstrated a statistically
lower overall mean itch score with alcaftadine
0.25% compared with olopatadine 0.2% (0.68
vs. 0.92, respectively; P = 0.0390; Fig. 3). Both
alcaftadine 0.25% and olopatadine 0.2% were
superior to placebo for achieving greater
reductions in mean itch scores at 3, 5, and
7 min post-CAC and over all time points
(P\0.0001 for both alcaftadine and
olopatadine versus placebo; Table 2).
Alcaftadine 0.25%-treated subjects consistently
demonstrated greater percentage reduction
in itching from baseline at 3, 5, and 7 min
post-CAC (-81.0%, -74.1%, and -70.6%,
respectively) compared with olopatadine
0.2%-treated subjects (-63.2%, -65.7%, and
-65.2%, respectively). For both actives, the
percentage reduction in itching from baseline
was superior over placebo at 3, 5, and 7 min
(-23.7%, -24.1%, and -30.2%, respectively).
The ocular itching primary efﬁcacy measure
was further assessed by comparing the
proportion of subjects in each group with
minimal itch (itch score \1) and zero itch
(itch score = 0). For subjects who met the
criteria for minimal itch or zero itch at all
three time points (3, 5, and 7 min), signiﬁcantly
higher proportions of subjects achieved overall
minimal itch and zero itch in the alcaftadine
0.25% and olopatadine 0.2% groups compared
with the placebo group (minimal itch,
P\0.0001; zero itch, P B 0.0006, for both
actives versus placebo; Fig. 4). A signiﬁcantly
greater proportion of alcaftadine 0.25%-treated
subjects achieved an itch score \1 compared
with olopatadine 0.2%-treated subjects over all
time points (76.1% vs. 58.1%; P = 0.0121); no
signiﬁcant differences were observed in the
proportion of subjects achieving zero itch
Fig. 1 Subject disposition
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P = 1.00; Fig. 4).
The distribution of the raw subject-reported
itch scores at baseline and 16 h post-treatment
instillation also was analyzed in which all itch
scores of each eye were included in the analysis
for all time points (3, 5, and 7 min; Fig. 5). A
shift to the left in the frequencies of scores
indicated improvement in both the magnitude
of relief and proportion of subjects whose
symptoms were alleviated. Subjects in all three
treatment groups (alcaftadine 0.25%,
olopatadine 0.2%, and placebo) showed a
similar distribution of itch scores at baseline,
with the majority of subjects reporting scores
between 2.0 and 3.5 over all time points post-
CAC (Fig. 5a). A signiﬁcantly larger proportion
of subjects who received treatment with
Table 1 Pooled analysis demographics (intent-to-treat population)
Characteristic
a Alcaftadine 0.25%
(n 5 96)
Olopatadine 0.2%
(n 5 95)
Placebo
(n 5 93)
All subjects
(n 5 284)
P value
Age, years 0.601
*
Mean ± SD 38.7 ± 13.1 37.9 ± 14.9 36.7 ± 12.6 37.8 ± 13.6
Min–max 12–70 12–74 14–68 12–74
Gender, n (%) 0.488

Male 33 (34.4) 33 (34.7) 39 (41.9) 105 (37.0)
Female 63 (65.6) 62 (65.3) 54 (58.1) 179 (63.0)
Ethnicity, n (%) 1.000

Hispanic or Latino 9 (9.4) 9 (9.5) 9 (9.7) 27 (9.5)
Not Hispanic or Latino 87 (90.6) 86 (90.5) 84 (90.3) 257 (90.5)
Race, n (%) 0.912

African American 12 (12.5) 15 (15.8) 16 (17.2) 43 (15.1)
Asian 19 (19.8) 20 (21.1) 20 (21.5) 59 (20.8)
Caucasian 56 (58.3) 53 (55.8) 53 (57.0) 162 (57.0)
Other 9 (9.4) 7 (7.4) 4 (4.3) 20 (7.0)
Iris color, n (%) \0.0001

Brown 118 (61.5) 118 (62.1) 124 (66.7) 360 (63.4)
Blue 38 (19.8) 40 (21.1) 22 (11.8) 100 (17.6)
Green 28 (14.6) 6 (3.2) 22 (11.8) 56 (9.9)
Hazel 4 (2.1) 20 (10.5) 14 (7.5) 38 (6.7)
Black 4 (2.1) 6 (3.2) 2 (1.1) 12 (2.1)
Gray 0 (0.0) 0 (0.0) 2 (1.1) 2 (0.4)
Max maximum, Min minimum, SD standard deviation
* Analysis of variance,
 Fisher’s exact test
a Percentages are based on the total number of subjects in each treatment group except for iris color, which is based on the
total number of eyes in each treatment group
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reported lower itch scores between 0 and 1.0
post-CAC compared with placebo-treated
subjects 16 h post-treatment instillation. A
greater leftward shift was observed in the
alcaftadine group than in the olopatadine
group; more subjects receiving alcaftadine
0.25% reported itch scores of 0 and 0.5 (Fig. 5b).
Safety
Sixteen adverse events were reported among
283 subjects comprising the safety population.
A total of 11 (3.9%) subjects, four treated with
alcaftadine 0.25%, ﬁve treated with olopatadine
0.2%, and two receiving placebo experienced at
least one adverse event. No adverse events were
considered to be related to study treatment, and
no serious adverse events were reported during
the course of the studies.
DISCUSSION
Two similarly designed multicenter studies were
conducted to compare the efﬁcacy and safety of
alcaftadine 0.25%, olopatadine 0.2%, and
placebo in relieving ocular itch and symptoms
related to allergic conjunctivitis. These are the
ﬁrst studies to compare the two agents approved
for once-daily use for the prevention of itching
associated with allergic conjunctivitis. The ﬁrst
study by Ackerman et al. [26] showed
differences in relief of itch between alcaftadine
0.25% and olopatadine 0.2% at the earliest time
point measured post-CAC (3 min) [26]. The
second study conﬁrmed the treatment
outcome differences between alcaftadine
0.25% and olopatadine 0.2% in preventing
signs and symptoms of allergic conjunctivitis
at 16 h post-treatment instillation [27, 28]. The
present analysis pools these ﬁndings in a large
data set and identiﬁed additional differentiation
over the 3, 5, and 7 min time points.
In the pooled analysis, alcaftadine 0.25%-
treated subjects experienced signiﬁcantly lower
mean ocular itch scores than olopatadine 0.2%-
treated subjects at 3 min post-CAC (P = 0.0006).
Fig. 2 Comparison of mean itch scores at baseline and
16 h after treatment instillation at 3 min post-conjunctival
allergen challenge (primary endpoint). Mean itch scores for
alcaftadine 0.25%, olopatadine 0.2%, and placebo.
*P\0.0001 for alcaftadine and olopatadine versus
placebo; **P = 0.0006 for alcaftadine versus olopatadine.
P values calculated using the two-sample t test
Fig. 3 Comparison of overall mean itch scores at baseline
and 16 h after treatment instillation over all time points
(3, 5, and 7 min) post-conjunctival allergen challenge.
Mean itch scores for alcaftadine 0.25%, olopatadine 0.2%,
and placebo. *P\0.0001 for alcaftadine and olopatadine
versus placebo; **P = 0.0390 for alcaftadine versus
olopatadine. P values calculated using the repeated
measures analysis of covariance model accounting for
treatment and time points
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solution also was superior to olopatadine 0.2%
ophthalmic solution in reducing mean itch
scores over all time points measured (3, 5, and
7 min; P = 0.0390). A signiﬁcantly greater
proportion of alcaftadine 0.25%-treated
subjects achieved minimal itch (itch score \1)
compared with olopatadine 0.2%-treated
subjects over all time points (P = 0.0121).
There were no statistically signiﬁcant
differences in the proportion of subjects with
zero itch (itch score = 0). Both alcaftadine and
olopatadine were superior to placebo at
relieving ocular itch associated with allergic
conjunctivitis in the pooled analysis.
Alcaftadine is unique among ocular
antihistamines in that it exhibits antagonistic
activity against H1,H 2, and H4 receptors
(although with lower afﬁnity than H1 and H2)
[20, 30]. The role of H4 receptors in allergic
conjunctivitis has not been fully elucidated;
in vitro studies suggest that histamine binding
to H4 receptors mediates eosinophil chemotaxis
[31]. In this pooled analysis, the distribution of
subject-reported itch scores at 16 h post-
treatment instillation over all time points
showed an improvement with alcaftadine
0.25% relative to olopatadine in the degree of
relief and the proportion of subjects whose
symptoms are alleviated following allergen
challenge, achieving a statistically signiﬁcant
greater percentage of subjects with scores of 0 or
0.5 relative to olopatadine 0.2% on a ﬁve-point
scale. In addition to this greater magnitude of
effect, in a previous study, alcaftadine 0.25%
had a rapid onset of action as measured at
15 min post-treatment instillation, which was
superior to that of olopatadine 0.1%, and
sustained duration of action up to 16 h post-
Table 2 Mean differences in ocular itch scores post-CAC at 16 h after treatment instillation
Time point post-CAC Difference in mean itch scores
Alcaftadine versus placebo Olopatadine versus placebo Alcaftadine versus olopatadine
3 min -1.57; P\0.0001* -1.20; P\0.0001* -0.37; P = 0.0006*
5 min -1.45; P\0.0001* -1.26; P\0.0001* -0.19; P = 0.0873*
7 min -1.17; P\0.0001* -1.14; P\0.0001* -0.03; P = 0.7751*
Over all time points -1.42; P\0.0001
 -1.19; P\0.0001
 -0.24; P = 0.0390

CAC conjunctival allergen challenge
* P values calculated using two-sample t test.
 P values calculated using repeated measures analysis of covariance model
accounting for treatment and time
Fig. 4 Comparison of overall percentage of subjects with
minimal itch and zero itch scores at 16 h after treatment
instillation. Percentage of subjects with minimal itch (itch
score\1) and zero itch for alcaftadine 0.25%, olopatadine
0.2%, and placebo at all time points post-conjunctival
allergen challenge. Subjects had to meet the itch score
criteria (\1 or 0) at 3, 5, and 7 min post-conjunctival
allergen challenge. *P\0.0001 for alcaftadine and
olopatadine versus placebo; **P B 0.0006 for alcaftadine
and olopatadine versus placebo; ***P = 0.0121 for
alcaftadine versus olopatadine. P values calculated using
Fisher’s exact test
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of allergic conjunctivitis, alcaftadine
demonstrated a greater effect than olopatadine
on eosinophil recruitment and stability of the
epithelial junctional protein, zonula occludens-
1[ 32]. Overall, these in vivo results suggest that
differences observed clinically between
alcaftadine and olopatadine may reﬂect a
greater ability of alcaftadine to prevent
allergen-activated disruption of the epithelial
barriers [33].
Similar to other reports of alcaftadine and
olopatadine [14, 15, 17, 26], treatment with
alcaftadine 0.25% and olopatadine 0.2% was
found to be generally well tolerated. While
eleven (3.9%) subjects experienced at least one
adverse event, none of the adverse events were
related to study treatment. In addition, there
were no serious adverse events reported at any
time during either study.
Limitations are inherent in any pooled
analysis, though the two studies pooled in the
present analysis demonstrated consistent
ﬁndings across measures evaluating relief of
ocular itching. In addition, both studies were
conducted employing the CAC model.
Additional long-term studies comparing
alcaftadine and olopatadine may further
Fig. 5 Distribution of itch scores at baseline (a) and 16 h
after treatment instillation (b). Itch scores of each eye at
baseline (untreated) and 16 h after treatment with
alcaftadine 0.25%, olopatadine 0.2%, and placebo at all
time points measured (3, 5, and 7 min) post-conjunctival
allergen challenge
1068 Adv Ther (2014) 31:1059–1071elucidate differences identiﬁed in these two
studies in the CAC model for allergic
conjunctivitis.
CONCLUSION
Evidence supports the use of alcaftadine 0.25%
for the prevention of itching associated with
allergic conjunctivitis, a condition affecting a
signiﬁcant number of individuals worldwide.
Compared with olopatadine 0.2% ophthalmic
solution, treatment with alcaftadine 0.25%
ophthalmic solution provided greater relief of
ocular itching at 16 h post-administration with
a similar safety proﬁle. Additional studies are
warranted to fully elucidate the underlying
mechanisms responsible for the observed
differences in treatment outcomes between the
alcaftadine 0.25% and olopatadine 0.2% once-
daily ophthalmic solutions.
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